ADMA Biologics Inc (ADMA) Stock Falls on Q1 2026 Earnings

ADMA Biologics Inc (ADMA) reported first-quarter 2026 results. Revenue was $114.5 million, down 0.27% year‑over‑year and below the consensus estimate of $144.6 million. Diluted earnings per share were $0.19, versus an estimate of $0.20.

Gross profit of $80.8 million, up 32.17% year‑over‑year.

Operating profit of $58.3 million, up 67.07% year‑over‑year.

Net income attributable to common shareholders of $45.3 million, up 68.48% year‑over‑year.

Diluted EPS of $0.19, an increase of 72.73% year‑over‑year.

Cash from operating activities of $58.2 million, a large year‑over‑year swing (-396.06%).

Purchases of property, plant and equipment of -$2.5 million (down 45.91% year‑over‑year).

Cash and cash equivalents of $138.2 million, up 92.88% year‑over‑year.

Total liabilities of $274.9 million, up 100.41% year‑over‑year.

Cost of sales improved to $33.7 million, down 37.17% year‑over‑year, supporting the stronger margin performance.

Shares declined 23.65% since market close following the release.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

ADMA Biologics Inc Insider Trading Activity

ADMA Biologics Inc insiders have traded $ADMA stock on the open market 11 times in the past 6 months. Of those trades, 2 have been purchases and 9 have been sales.

Here’s a breakdown of recent trading of $ADMA stock by insiders over the last 6 months:

ADAM S GROSSMAN (President and CEO) has made 0 purchases and 8 sales selling 84,000 shares for an estimated $1,407,630.
STEVE ELMS has made 2 purchases buying 14,000 shares for an estimated $217,420 and 0 sales.
KAITLIN M. KESTENBERG-MESSINA (COO and SVP, Compliance) sold 10,096 shares for an estimated $157,800

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

EARLY ACCESS

Receive ADMA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

ADMA Biologics Inc Hedge Fund Activity

We have seen 166 institutional investors add shares of ADMA Biologics Inc stock to their portfolio, and 211 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANUS HENDERSON GROUP PLC added 3,838,158 shares (+3906.1%) to their portfolio in Q4 2025, for an estimated $70,008,001
THRIVENT FINANCIAL FOR LUTHERANS removed 3,631,662 shares (-95.8%) from their portfolio in Q1 2026, for an estimated $32,721,274
CAPITAL RESEARCH GLOBAL INVESTORS added 3,383,559 shares (+104.0%) to their portfolio in Q4 2025, for an estimated $61,716,116
OBERWEIS ASSET MANAGEMENT INC/ removed 2,712,040 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $49,467,609
UBS GROUP AG removed 2,419,067 shares (-52.9%) from their portfolio in Q1 2026, for an estimated $21,795,793
SACHEM HEAD CAPITAL MANAGEMENT LP added 2,415,000 shares (+27.0%) to their portfolio in Q4 2025, for an estimated $44,049,599
PERPETUAL LTD removed 2,119,291 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $38,655,867

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

ADMA Biologics Inc Price Targets

Multiple analysts have issued price targets for $ADMA recently. We have seen 2 analysts offer price targets for $ADMA in the last 6 months, with a median target of $22.5.

Here are some recent targets:

Gary Nachman from Canaccord Genuity set a target price of $21.0 on 04/21/2026
Anthony Petrone from Mizuho set a target price of $24.0 on 04/13/2026